Correlation Between EIT-based Pulse Wave Method for Pulmonary Perfusion Monitoring and Pulmonary … (NCT07385963) | Clinical Trial Compass
Not Yet RecruitingNot Applicable
Correlation Between EIT-based Pulse Wave Method for Pulmonary Perfusion Monitoring and Pulmonary Artery Catheter-based Stroke Volume Measurement
China19 participantsStarted 2026-02-02
Plain-language summary
The goal of this clinical study is to learn if a new, non-invasive monitoring method called EIT Pulse Wave can accurately measure blood flow to the lungs (pulmonary perfusion) and predict heart stroke volume (SV) in critically ill patients. It will also learn about the safety of this monitoring approach. The main questions it aims to answer are:
How well does the EIT Pulse Wave measurement of lung blood flow correlate with the SV measured by the standard method (Swan-Ganz catheter)? Can we build a reliable model to predict SV non-invasively using the EIT Pulse Wave signal? Researchers will compare the EIT Pulse Wave measurements directly with the Swan-Ganz catheter measurements to see if the new method is accurate.
Participants will:
Be critically ill adults in the ICU who are already receiving mechanical ventilation and have a Swan-Ganz catheter in place for medical reasons.
Undergo simultaneous monitoring using both the EIT device and the Swan-Ganz catheter every 30 minutes for up to 48 hours.
Have their ventilator settings adjusted to different levels as part of the study protocol while both measurements are recorded.
Who can participate
Age range
18 Years – 80 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Critically ill patients requiring mechanical ventilation support.
* Patients meeting the 2023 global ARDS definition and/or shock patients receiving vasoactive medication therapy.
* Patients who have already had a pulmonary artery catheter inserted due to clinical needs.
Exclusion Criteria:
* Age under 18 years or over 80 years.
* Patients with severe obesity (BMI ≥ 35 kg/m²).
* Pregnant or lactating women.
* Pulmonary embolism.
* Patients undergoing ECMO therapy.
* Arrhythmia.
* Contraindications to EIT monitoring.
* Contraindications to pulmonary artery catheter use.
* Failure to provide signed informed consent.
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Correlation between EIT Pulmonary Perfusion Signal and Catheter-measured Stroke Volume
Timeframe: From the start of synchronous monitoring for each enrolled subject until the end of the monitoring period (up to 48 hours).
Trial details
NCT IDNCT07385963
SponsorUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology